- IBDEI1XQ ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,30907,1,3,0)
- ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
- ;;^UTILITY(U,$J,358.3,30907,1,4,0)
- ;;=4^N04.2
- ;;^UTILITY(U,$J,358.3,30907,2)
- ;;=^5015533
- ;;^UTILITY(U,$J,358.3,30908,0)
- ;;=N04.3^^123^1597^56
- ;;^UTILITY(U,$J,358.3,30908,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30908,1,3,0)
- ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
- ;;^UTILITY(U,$J,358.3,30908,1,4,0)
- ;;=4^N04.3
- ;;^UTILITY(U,$J,358.3,30908,2)
- ;;=^5015534
- ;;^UTILITY(U,$J,358.3,30909,0)
- ;;=N04.4^^123^1597^54
- ;;^UTILITY(U,$J,358.3,30909,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30909,1,3,0)
- ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
- ;;^UTILITY(U,$J,358.3,30909,1,4,0)
- ;;=4^N04.4
- ;;^UTILITY(U,$J,358.3,30909,2)
- ;;=^5015535
- ;;^UTILITY(U,$J,358.3,30910,0)
- ;;=N04.5^^123^1597^57
- ;;^UTILITY(U,$J,358.3,30910,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30910,1,3,0)
- ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
- ;;^UTILITY(U,$J,358.3,30910,1,4,0)
- ;;=4^N04.5
- ;;^UTILITY(U,$J,358.3,30910,2)
- ;;=^5015536
- ;;^UTILITY(U,$J,358.3,30911,0)
- ;;=N04.6^^123^1597^52
- ;;^UTILITY(U,$J,358.3,30911,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30911,1,3,0)
- ;;=3^Nephrotic syndrome w/ dense deposit disease
- ;;^UTILITY(U,$J,358.3,30911,1,4,0)
- ;;=4^N04.6
- ;;^UTILITY(U,$J,358.3,30911,2)
- ;;=^5015537
- ;;^UTILITY(U,$J,358.3,30912,0)
- ;;=N04.7^^123^1597^53
- ;;^UTILITY(U,$J,358.3,30912,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30912,1,3,0)
- ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
- ;;^UTILITY(U,$J,358.3,30912,1,4,0)
- ;;=4^N04.7
- ;;^UTILITY(U,$J,358.3,30912,2)
- ;;=^5015538
- ;;^UTILITY(U,$J,358.3,30913,0)
- ;;=N04.8^^123^1597^60
- ;;^UTILITY(U,$J,358.3,30913,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30913,1,3,0)
- ;;=3^Nephrotic syndrome w/ other morphologic changes
- ;;^UTILITY(U,$J,358.3,30913,1,4,0)
- ;;=4^N04.8
- ;;^UTILITY(U,$J,358.3,30913,2)
- ;;=^5015539
- ;;^UTILITY(U,$J,358.3,30914,0)
- ;;=N04.9^^123^1597^61
- ;;^UTILITY(U,$J,358.3,30914,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30914,1,3,0)
- ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
- ;;^UTILITY(U,$J,358.3,30914,1,4,0)
- ;;=4^N04.9
- ;;^UTILITY(U,$J,358.3,30914,2)
- ;;=^5015540
- ;;^UTILITY(U,$J,358.3,30915,0)
- ;;=N05.0^^123^1597^49
- ;;^UTILITY(U,$J,358.3,30915,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30915,1,3,0)
- ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
- ;;^UTILITY(U,$J,358.3,30915,1,4,0)
- ;;=4^N05.0
- ;;^UTILITY(U,$J,358.3,30915,2)
- ;;=^5015541
- ;;^UTILITY(U,$J,358.3,30916,0)
- ;;=N05.1^^123^1597^48
- ;;^UTILITY(U,$J,358.3,30916,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30916,1,3,0)
- ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
- ;;^UTILITY(U,$J,358.3,30916,1,4,0)
- ;;=4^N05.1
- ;;^UTILITY(U,$J,358.3,30916,2)
- ;;=^5015542
- ;;^UTILITY(U,$J,358.3,30917,0)
- ;;=N05.2^^123^1597^45
- ;;^UTILITY(U,$J,358.3,30917,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30917,1,3,0)
- ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
- ;;^UTILITY(U,$J,358.3,30917,1,4,0)
- ;;=4^N05.2
- ;;^UTILITY(U,$J,358.3,30917,2)
- ;;=^5015543
- ;;^UTILITY(U,$J,358.3,30918,0)
- ;;=N05.3^^123^1597^46
- ;;^UTILITY(U,$J,358.3,30918,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30918,1,3,0)
- ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XQ 3762 printed Jan 18, 2025@03:19:03 Page 2
- IBDEI1XQ ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,30907,1,3,0)
- +2 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
- +3 ;;^UTILITY(U,$J,358.3,30907,1,4,0)
- +4 ;;=4^N04.2
- +5 ;;^UTILITY(U,$J,358.3,30907,2)
- +6 ;;=^5015533
- +7 ;;^UTILITY(U,$J,358.3,30908,0)
- +8 ;;=N04.3^^123^1597^56
- +9 ;;^UTILITY(U,$J,358.3,30908,1,0)
- +10 ;;=^358.31IA^4^2
- +11 ;;^UTILITY(U,$J,358.3,30908,1,3,0)
- +12 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
- +13 ;;^UTILITY(U,$J,358.3,30908,1,4,0)
- +14 ;;=4^N04.3
- +15 ;;^UTILITY(U,$J,358.3,30908,2)
- +16 ;;=^5015534
- +17 ;;^UTILITY(U,$J,358.3,30909,0)
- +18 ;;=N04.4^^123^1597^54
- +19 ;;^UTILITY(U,$J,358.3,30909,1,0)
- +20 ;;=^358.31IA^4^2
- +21 ;;^UTILITY(U,$J,358.3,30909,1,3,0)
- +22 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
- +23 ;;^UTILITY(U,$J,358.3,30909,1,4,0)
- +24 ;;=4^N04.4
- +25 ;;^UTILITY(U,$J,358.3,30909,2)
- +26 ;;=^5015535
- +27 ;;^UTILITY(U,$J,358.3,30910,0)
- +28 ;;=N04.5^^123^1597^57
- +29 ;;^UTILITY(U,$J,358.3,30910,1,0)
- +30 ;;=^358.31IA^4^2
- +31 ;;^UTILITY(U,$J,358.3,30910,1,3,0)
- +32 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
- +33 ;;^UTILITY(U,$J,358.3,30910,1,4,0)
- +34 ;;=4^N04.5
- +35 ;;^UTILITY(U,$J,358.3,30910,2)
- +36 ;;=^5015536
- +37 ;;^UTILITY(U,$J,358.3,30911,0)
- +38 ;;=N04.6^^123^1597^52
- +39 ;;^UTILITY(U,$J,358.3,30911,1,0)
- +40 ;;=^358.31IA^4^2
- +41 ;;^UTILITY(U,$J,358.3,30911,1,3,0)
- +42 ;;=3^Nephrotic syndrome w/ dense deposit disease
- +43 ;;^UTILITY(U,$J,358.3,30911,1,4,0)
- +44 ;;=4^N04.6
- +45 ;;^UTILITY(U,$J,358.3,30911,2)
- +46 ;;=^5015537
- +47 ;;^UTILITY(U,$J,358.3,30912,0)
- +48 ;;=N04.7^^123^1597^53
- +49 ;;^UTILITY(U,$J,358.3,30912,1,0)
- +50 ;;=^358.31IA^4^2
- +51 ;;^UTILITY(U,$J,358.3,30912,1,3,0)
- +52 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
- +53 ;;^UTILITY(U,$J,358.3,30912,1,4,0)
- +54 ;;=4^N04.7
- +55 ;;^UTILITY(U,$J,358.3,30912,2)
- +56 ;;=^5015538
- +57 ;;^UTILITY(U,$J,358.3,30913,0)
- +58 ;;=N04.8^^123^1597^60
- +59 ;;^UTILITY(U,$J,358.3,30913,1,0)
- +60 ;;=^358.31IA^4^2
- +61 ;;^UTILITY(U,$J,358.3,30913,1,3,0)
- +62 ;;=3^Nephrotic syndrome w/ other morphologic changes
- +63 ;;^UTILITY(U,$J,358.3,30913,1,4,0)
- +64 ;;=4^N04.8
- +65 ;;^UTILITY(U,$J,358.3,30913,2)
- +66 ;;=^5015539
- +67 ;;^UTILITY(U,$J,358.3,30914,0)
- +68 ;;=N04.9^^123^1597^61
- +69 ;;^UTILITY(U,$J,358.3,30914,1,0)
- +70 ;;=^358.31IA^4^2
- +71 ;;^UTILITY(U,$J,358.3,30914,1,3,0)
- +72 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
- +73 ;;^UTILITY(U,$J,358.3,30914,1,4,0)
- +74 ;;=4^N04.9
- +75 ;;^UTILITY(U,$J,358.3,30914,2)
- +76 ;;=^5015540
- +77 ;;^UTILITY(U,$J,358.3,30915,0)
- +78 ;;=N05.0^^123^1597^49
- +79 ;;^UTILITY(U,$J,358.3,30915,1,0)
- +80 ;;=^358.31IA^4^2
- +81 ;;^UTILITY(U,$J,358.3,30915,1,3,0)
- +82 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
- +83 ;;^UTILITY(U,$J,358.3,30915,1,4,0)
- +84 ;;=4^N05.0
- +85 ;;^UTILITY(U,$J,358.3,30915,2)
- +86 ;;=^5015541
- +87 ;;^UTILITY(U,$J,358.3,30916,0)
- +88 ;;=N05.1^^123^1597^48
- +89 ;;^UTILITY(U,$J,358.3,30916,1,0)
- +90 ;;=^358.31IA^4^2
- +91 ;;^UTILITY(U,$J,358.3,30916,1,3,0)
- +92 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
- +93 ;;^UTILITY(U,$J,358.3,30916,1,4,0)
- +94 ;;=4^N05.1
- +95 ;;^UTILITY(U,$J,358.3,30916,2)
- +96 ;;=^5015542
- +97 ;;^UTILITY(U,$J,358.3,30917,0)
- +98 ;;=N05.2^^123^1597^45
- +99 ;;^UTILITY(U,$J,358.3,30917,1,0)
- +100 ;;=^358.31IA^4^2
- +101 ;;^UTILITY(U,$J,358.3,30917,1,3,0)
- +102 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
- +103 ;;^UTILITY(U,$J,358.3,30917,1,4,0)
- +104 ;;=4^N05.2
- +105 ;;^UTILITY(U,$J,358.3,30917,2)
- +106 ;;=^5015543
- +107 ;;^UTILITY(U,$J,358.3,30918,0)
- +108 ;;=N05.3^^123^1597^46
- +109 ;;^UTILITY(U,$J,358.3,30918,1,0)
- +110 ;;=^358.31IA^4^2
- +111 ;;^UTILITY(U,$J,358.3,30918,1,3,0)
- +112 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph